Immunomodulating IL-6 activity by murine monoclonal antibodies.
The human anti-mouse immunoglobulin antibody (HAMA) response, which occurs frequently after injection of murine monoclonal antibodies (MAb) directed against cellular targets, has been reported extensively in several studies. We analysed here HAMA in 12 patients (six with multiple myeloma, MM, and six with metastatic renal cell carcinoma, MRCC) who were treated with B-E8, an IgG1 MAb against interleukin-6 (IL-6). Efficiency of the treatment was evidenced by the drop in the serum levels of C reactive protein (CRP), of which the in vivo production is under the control of IL-6. Three patients with MM and the six patients with MRCC became immunized to the injected MAb. HAMA appeared between days 7 and 15 after the beginning of the treatment. The nine patients made IgG antibodies; four also made IgM. All of immunized patients made anti-idiotype antibodies specific to B-E8. Two of them also developed HAMA directed to murine IgG1 isotype; in these two patients B-E8 MAb cleared rapidly from the circulation with loss of treatment efficiency. In the patients who developed only anti-idiotype antibodies, serum levels of B-E8 remained unchanged and CRP production remained inhibited, indicating that treatment efficiency was not affected by the presence of HAMA. Circulating B-E8 MAb were still able to bind to IL-6 and to inhibit IL-6-independent proliferation despite the presence of anti-idiotypic HAMA. Therefore, in contrast to HAMA against MAb directed against cellular targets, HAMA against anti-IL-6 MAb idiotopes led neither to clearance nor to functional inactivation of the injected MAb.(ABSTRACT TRUNCATED AT 250 WORDS)
Brochier
J
J
INSERM U291, Montpellier, France.
Legouffe
E
E
Liautard
J
J
Gaillard
J P
JP
Mao
L Q
LQ
Bataille
R
R
Rossi
J F
JF
Klein
B
B
D000276:Adjuvants, Immunologic / Q000502:physiology*; D000328:Adult; D000368:Aged; D000818:Animals; D000910:Antibodies, Heterophile / Q000009:adverse effects / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015850:Interleukin-6 / Q000276:immunology*; D007680:Kidney Neoplasms / Q000556:secondary / Q000628:therapy; D008297:Male; D051379:Mice; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D000093242:Interleukin-6 Inhibitors
D000276:Adjuvants, Immunologic; D000910:Antibodies, Heterophile; D000911:Antibodies, Monoclonal; D002097:C-Reactive Protein; D015850:Interleukin-6; D000093242:Interleukin-6 Inhibitors